Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CV Technologies

This article was originally published in The Tan Sheet

Executive Summary

Canadian biopharmaceutical firm announces U.S. FDA clearance of investigational new drug application for CVT-E002, a North American ginseng extract intended for use as a prophylactic against acute respiratory infection. Recruiting of 200 frail, older adults from nursing homes will begin shortly for a four-month, Phase II clinical trial conducted by Eastern Virginia Medical School in Norfolk. CVT's six FX dietary supplement products are marketed in the U.S. by Amrion, a division of Whole Foods, and are sold in Canada under the HerbTech name. CVT has approximately 80 dietary supplement and five Rx products in the pipeline and is seeking alliances with pharmaceutical firms

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts